Abbott Delivers High Single-Digit Sales Growth and Double-Digit Earnings Per Share Growth in Q1 2025

Abbott Delivers High Single-Digit Sales Growth and Double-Digit Earnings Per Share Growth in Q1 2025


The first quarter of 2025 has been a significant period for Abbott, with the company delivering high single-digit sales growth and double-digit earnings per share growth. In an increasingly dynamic environment influenced by new tariff policies, Abbott's diversified business model has proven to be a major advantage.

According to Robert Ford, Chairman and Chief Executive Officer of Abbott, the company is well-positioned to navigate the complexities arising from global circumstances such as the repercussions of the global pandemic, global financial crisis, and geopolitical events. With 90 manufacturing sites around the world and decades of experience executing its global network strategy, Abbott is prepared to adeptly manage the impact of tariffs.

In terms of sales growth, Abbott achieved a 7% increase in the first quarter, with adjusted earnings per share growing 11% versus the prior year. This performance finished at the high end of the company's guidance range and demonstrates its ability to deliver strong financial results despite challenging global conditions.

The Nutrition segment was a key driver of growth for Abbott in Q1, with sales increasing 7% in the quarter. High single-digit growth was achieved in Adult Nutrition, while double-digit growth was recorded in U.S. Pediatric Nutrition. The company's relentless focus on research, innovation, and product quality has made its Similac family of products the #1 choice for parents in the United States.

Adult Nutrition also saw strong growth, with sales increasing 8.5% due to growing demand for Abbott's Ensure family of products. These products serve as a source of complete and balanced nutrition for people with a wide range of nutritional needs.

In contrast, the Diagnostics segment experienced a decline in sales of 5% in Q1, primarily due to a much weaker COVID-19 testing season. However, this slowdown was not unexpected given the reduced demand for COVID-related products. Abbott's Rapid Diagnostics business was impacted by this decline, but the company remains focused on delivering innovative solutions across its various segments.

Phil Boudreau, Executive Vice President, Finance and Chief Financial Officer of Abbott, will provide further commentary on the company's financial performance in Q1 2025 during the conference call. Investors can expect to hear more about the company's strategy for managing tariffs and delivering strong sales growth in a rapidly evolving global environment.

Read more